Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genteric Inc.

Latest From Genteric Inc.

Juvaris BioTherapeutics Inc.

Juvaris BioTherapeutics Inc.'s technology is an offshoot of gene therapy work originally conducted at Valentis. Researchers there discovered that their DNA/lipid delivery combination elicited a mild immune response at the lowest dose. Juvaris has used the technology to develop two classes of products: JuvImmune is made up of the DNA/lipid combination without an antigen and is intended to boost the immune response. Combined with vaccines, where it boosts the intensity of the immune response, the technology is called JuvaVax.

Genteric Inc.

Genteric is harnessing the body's ductal system to get genes into the gastrointestinal organs and on into the circulation, without directly confronting the circulatory system. The firm believes this direct route will improve transfection rates and reduce immune reactions, regardless of the sort of vector--and has been pitching gene-therapy companies on the concept. So far, they've been hard to convince, but Genteric is confident they will come to appreciate the benefits of its delivery method.
BioPharmaceutical Strategy

Start-Up Previews (04/01)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Vision Correction, features profiles of Calhoun Vision Inc., EyeTech Pharmaceuticals Inc., Quest Vision and Visual Pathways Inc. Plus these selected Start-Ups across Health Care: Activx Biosciences Inc., Ark Therapeutics Ltd., Genteric Inc. and Vyteris Inc.
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Genteric Inc.
  • Senior Management
  • Mitchell H Finer, PhD, Pres. & CEO
    Donald D Huffman, VP, Fin., Admin. & CFO
    Keith F Lenden, Dir., Bus. Dev.
  • Contact Info
  • Genteric Inc.
    Phone: (510) 749-6060
    1650 Harbor Bay Pkwy.
    Alameda, CA 94502